BCLI closes @ 7.50 > BrainStorm's CEO, Tony Fiorino, MD, PhD, stated, "We are very excited to share the final results of this study. Professor Karussis presented a very positive and well-received interim analysis of this study at the Joint Congress of European Neurology in June 2014, and the final results include data from several additional subjects and analyses conducted by our independent statisticians. The interim analysis of this study, and results of our prior phase 1/2 study, have shown that a single dose of NurOwn™ is safe and can provide clinically meaningful benefits to ALS patients, such as a reduction in the rate of progression, and in some patients, actual improvements in function. The final results will extend these findings and allow us to move forward with a presentation and publication strategy so that we may share these important data with our medical and scientific colleagues."
Conference call and webcast details are below.
Monday, January 5, 2015 at 8:30 AM Eastern Standard Time
News 
Market Data 
Discover 
AI
